Updated on August 27, 2021
Effective August 30, 2021
We acknowledge any potential frustration in enabling treatment continuity for your patients prescribed Actemra IV. We are committed to communicating with you as the situation evolves.
For the most up-to-date information on product availability across the Actemra IV and/or SC formulations, please contact your authorized distributors. For Actemra IV availability information, customers may refer to the distributors’ online ordering portal or customer service line.
Update to Return Goods Policy for Actemra IV:
We have updated our Return Goods Policy as it relates to Actemra IV. Genentech will not accept returns for Actemra IV purchased on or after August 30, 2021 until further notice. The updated policy for expired returns is now available.
For drop-ship orders placed prior to August 24, please contact your authorized distributor for a status update.
To receive email alerts as this page is updated, please sign up below.
Protecting your patients from illegitimate medicines
ACTEMRA is available only through authorized distributors that have made a commitment to product integrity.
Be cautious of new or unfamiliar distributors that offer ACTEMRA at substantially lower prices that may be "too good to be true"; the product being offered may be illegitimate.
If you suspect that you have received an illegitimate medicine, contact Genentech's Product Complaint Hotline at 1-800-334-0290, and file a report with the FDA’s Office of Criminal Investigations (OCI): call 1-800-551-3989 or visit www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm